Objective Biomarkers in osteoarthritis (OA) could serve as objective clinical indicators for various disease parameters, and act as surrogate endpoints in clinical trials for disease-modifying drugs. The aim of this systematic review was to produce a comprehensive list of candidate molecular biomarkers for knee OA after the 2013 ESCEO review and discern whether any have been studied in sufficient detail for use in clinical settings. Design MEDLINE and Embase databases were searched between August 2013 and May 2018 using the keywords “knee osteoarthritis,” “osteoarthritis,” and “biomarker.” Studies were screened by title, abstract, and full text. Human studies on knee OA that were published in the English language were included. Excluded were studies on genetic/imaging/cellular markers, studies on participants with secondary OA, and publications that were review/abstract-only. Study quality and bias were assessed. Statistically significant data regarding the relationship between a biomarker and a disease parameter were extracted. Results A total of 80 studies were included in the final review and 89 statistically significant individual molecular biomarkers were identified. C-telopeptide of type II collagen (CTXII) was shown to predict progression of knee OA in urine and serum in multiple studies. Synovial fluid vascular endothelial growth factor concentration was reported by 2 studies to be predictive of knee OA progression. Conclusion Despite the clear need for biomarkers of OA, the lack of coordination in current research has led to incompatible results. As such, there is yet to be a suitable biomarker to be used in a clinical setting.

Introduction: Smoking cessation following lung cancer diagnosis is recommended to improve patient outcomes. Electronic Patient Reported Outcome Measures (ePROMs) may be useful for identifying and facilitating cessation support in patients that continue to smoke after a cancer diagnosis. The primary aim was to investigate the level of agreement between clinician-reported and self-reported patient smoking status during the first visit to a cancer centre (I). Secondary aims included investigating differences between cancer-specific characteristics between never smokers and current/exsmokers (IIA), and the self-reported frequency of smoking cessation after diagnosis of lung cancer (IIB). Methods: Retrospective single-centre study carried out at a tertiary cancer centre in the UK. Lung cancer patients that completed at least one ePROM questionnaire within 6 weeks of their first visit to the cancer centre (baseline), between February 2019 and February 2020, were included in the study. All ePROM questionnaires included a question regarding smoking status to allow comparison with the clinician records. Patients were offered these electronic questionnaires at each subsequent visit to the hospital. Results: Of 195 patients included, 24 (12.3%) demonstrated discordance between clinician-

Perioperative chemotherapy is standard of care in the curative treatment of locally advanced esophagogastric adenocarcinoma in the UK. Previously used MAGIC triplet is becoming less frequently used in favor of superior FLOT quadruplet. There is however large number of patients who don't undergo adjuvant component of both of these perioperative regimens. This study aimed to investigate factors which are associated with not receiving adjuvant chemotherapy after neoadjuvant chemotherapy followed by surgical resection for esophagogastric adenocarcinoma. All patient receiving neoadjuvant chemotherapy for esophagogastric adenocarcinoma followed by curative surgery during 2010 till 2019 were identified from prospectively maintained single institution database. Patients who died in-hospital or within 90 days of surgery were excluded from analyses. Risk factors which could be associated with receiving/not receiving adjuvant component were studied. Mann U Whitney and chi-square test were used as appropriate. Multivariable logistic regression was carried out to identify risk factors independently predictive of not receiving adjuvant chemotherapy. Analyses included 624 patients of whom 273 received adjuvant chemotherapy (44%). This included ECX/ECF in 233 patients, EOX in 5 patients, FLOT in 22 patients and other/unknown regimens in 13 patients. Age, Charlson comorbidity index, return to theatre, severe postoperative complications (Clavien-Dindo grade III+) and R1 resection were associated with not receiving adjuvant chemotherapy (p 0.005, p 0.006, p 0.026, p 0.043, p 0.004 respectively). Statistically significant variables were entered into multivariable logistic regression model. Only R1 resection was independently associated with not receiving adjuvant component (OR 0.18, p 0.007). This study confirms that only less than half of patients who undergo neoadjuvant chemotherapy followed by surgery with curative intent receive adjuvant chemotherapy. Reasons for this are multifactorial but age, comorbidities, severe complications and positive longitudinal margin might play important role. These results also highlight the importance of prevention, early detection and appropriate management of postoperative complications.

No abstract